HPV vaccination with Gardasil®: A breakthrough in women's health

Expert Opinion on Biological Therapy

Volumn 6, Issue 11, 2006, Pages 1223-1227

  Hanna, Engy ^b   Bachmann, Gloria ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b Cab 2104 ^*

Author keywords

Cervical cancer; HPV; Human papillomavirus; Vaccination

Indexed keywords

ALPHA INTERFERON; GARDASIL; IMIDAZOQUINOLINE DERIVATIVE; PODOPHYLLIN; TRICHLOROACETIC ACID; WART VIRUS VACCINE;

CLINICAL TRIAL; CONDYLOMA; CRYOTHERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROSURGERY; HEADACHE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; INJECTION SITE PAIN; INJECTION SITE REACTION; LOW LEVEL LASER THERAPY; PAPANICOLAOU TEST; PHOTODYNAMIC THERAPY; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRUS PARTICLE; WART VIRUS;

CARCINOMA IN SITU; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRECANCEROUS CONDITIONS; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 33750826359     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.11.1223     Document Type: Review

References (22)

1. WALBOOMERS JM, JACOBS MV, MANOS MM et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. (1999) 189:12-19.
2. CLIFFORD GM, SMITH JS, PLUMMER M, MUNOZ N, FRANCESCHI S: Human papillomavirus types in invasive cervical cancer worldwide a meta-analysis. Br. J. Cancer (2003) 88:63-73.
3. BOSCH FX, DE SANJOSE S: Chapter 1: Human papillomavirus and cervical cancer - burden and assessment of causality. J. Natl. Cancer Inst. Monogr. (2003) 31:3-13.
4. SCHEURER ME, TORTOLERO-LUNA G, ADLER-STORTHZ K: Human papillomavirus infection: biology, epidemiology, and prevention. Int. J. Gynecol. Cancer (2005) 15:727-746.
5. LOCKWOOD-RAYERMANN S: Characteristics of participation in cervical cancer screening. Cancer Nurs. (2004) 27(5):353-363.
6. MAO C, KOUTSKY LA, AULT KA et al.: Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia. A randomized controlled trial. Obstet. Gynecol. (2006) 107:18-27.
7. MANHART LE, KOUTSKY LA: Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex. Transm. Dis. (2002) 29(11):725-735.
8. STANLEY M: Chapter 17: Genital human papillomavirus infections - current and prospective therapies. J. Natl. Cancer Inst. Monogr. (2003) 31:117-124.
9. SHERMAN ME, SHIFFMAN M, HERRERO R et al.: Performance of a semiautomated papanicolaou smear screening system. Cancer (1998) 84(5):273-280.
10. KOUTSKY LA, AULT KA, WHEELER CM et al.: A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. (2002) 347(21):1645-1651.
11. POLAND GA, JACOBSON RM, KOUTSKY LA et al.: Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial. Mayo Clin. Proc. (2005) 80(5):601-610.
12. HARRO CD, PANG YS, RODEN RB et al.: Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl Cancer Inst. (2001) 93(4):284-292.
13. AULT KA, GIULIANO AR, EDWARDS RP et al.: A Phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine (2004) 22:3004-3007.
14. FIFE KH, WHEELER CM, KOUTSKY LA et al.: Dose-ranging studies of the safety and immunogenicity of human papillomavirus type 11 and type 16 virus-like particle candidate vaccines in young healthy women. Vaccine (2004) 22:2943-2952.
15. EVANS TG, BONNEZ W, ROSE RC et al.: A Phase I study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J. Infect. Dis. (2001) 183:1485-1493.
16. EMENY RT, WHEELER CM, JANSEN KU et al.: Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J. Virol. (2002) 76(15):7832-7842.
17. BROWN DR, FIFE KH, WHEELER CM et al.: Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine (2004) 22:2936-2942.
18. VILLA LL, COSTA RLR, PETTA CA et al.: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre Phase II efficacy trial. Lancet Oncol. (2005) 6:271-278.
19. http://www.cancer.org/downloads/STT/CAF F2005f4PWSecured.pdf American Cancer Society. Cancer facts and figures 2005.
20. http://www.ahrq.gov/clinic/uspstf/uspscerv.htm US Preventive Services Task Force: Screening Recommendations for Cervical Cancer (2003).
21. http://www.kaisernetwork.org/daily_reports/rep_index.cfm?DRJD=32992 Merck's HPV vaccine in Phase II trial 100% effective for two strains causing 70% of cervical cancer cases. Kaiser Network Daily Reports (2005).
22. http://www.merck.com/newsroom/press_releases/research_and_development Merck's investigational vaccine GARDASIL prevented 100 percent of cervical pre-cancers and non-invasive cervical cancers associated with HPV types 16 and 18 in a new clinical study (2005).